同犇投资是一家有特色的阳光私募。公司成立于2014年1月，实缴资本1000万，2014年5月4日获得私募 投资基金管理人登记证书，是为数不多的由新财富最佳分析师创建的阳光私募，也是"五年金牌分析师 转型阳光私募"的唯一团队。公司总经理、投资总监童驯先生02-13年曾在上海申银万国证券研究所工作 12年，08-12年连续五年荣获新财富食品饮料行业最佳分析师第一名，擅长大消费投资。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 2）珀莱雅 （同犇投资参与公司业绩说明会） 调研纪要：2024年，珀莱雅成为国内首个营收突破百亿的美妆公司，提出'双十战略'，目标在未来十年 跻身全球化妆品行业前十。主品牌珀莱雅在中国市场的市占率仍有提升空间，将重点发展源力、能量、 美白、底妆等系列。线上渠道将丰富产品矩阵，提升运营能力；线下渠道关注新形式，持续布局。护肤 品牌定位明确，彩妆品牌聚焦专业领域，洗护品牌定位中高端及功效型。出海方面，公司将聚焦东南亚 市场，开发适合当地需求的产品，并与本土渠道商合作；投资方面，将通过投资丰富品牌和产品矩阵， 满足不同 ...

事件 公司发布2024 年年报与2025 年1 季报：2024 年营收107.78 亿元 （同比+21.0%），归母净利润15.52 亿 元（同比+30.0%），扣非归母净利润15.22亿元（同比+29.6%）；2025Q1 营收23.59 亿元 （同比 +8.1%），归母净利润3.9 亿元（同比+28.9%），扣非归母净利润3.79 亿元（同比+29.8%）。 2024 年营收过百亿大关，利润增长不改龙头底色2024Q4 与2025Q1 均在收入稳健基础上实现20%+利润 增长，表观上受益于综合毛利率提升与费用端降本增效。我们认为，2024H2 电商平台流量竞争激烈， 美妆品牌利润率多承压，珀莱雅利润率逆势提升，背后是公司四大单品矩阵系列支撑（客单价与复购率 提升）、精细化运营与成本管控能力强、2020 年转型以来不断积蓄的品牌势能。 "大单品策略"持续夯实，看好美白/油皮等品类增量2024 年以来公司持续夯实"大单品策略"，包括升级 双抗系列、红宝石系列、源力系列核心大单品，丰富能量系列新品，全新推出盾护防晒、超膜银管防 晒、针对美白的光学系列、针对油皮的净源系列。存量大单品系列升级延长生命周期、美白/油 ...

Group 1: Market Overview - A-shares experienced a decline with a trading volume of 1.07 trillion yuan, while the largest consumer ETF (159928) slightly dropped by 0.37% with a trading volume of nearly 300 million yuan, indicating high trading activity [1] - Over the past 60 days, there has been a continuous inflow of funds into consumer stocks, totaling nearly 2.6 billion yuan [1] Group 2: Company Performance - Proya, a leading domestic beauty brand, has gained market attention due to its impressive annual and quarterly reports, achieving a consecutive increase in stock price [3] - Proya's revenue for 2024 is projected to reach 10.234 billion yuan, with online sales accounting for 95.06% of total revenue, reflecting strong organizational efficiency and brand growth potential [3][4] - In Q1 2024, Proya's net profit attributable to shareholders increased by 29% year-on-year, showcasing improved operational quality [4] Group 3: Consumer Sector Earnings - Wuliangye reported Q1 2024 revenue of 36.94 billion yuan, a year-on-year increase of 6.05%, with a net profit of 14.86 billion yuan, also up by 5.8% [5] - Among the 41 constituent stocks of the consumer ETF (159928), 22 have released Q1 reports, with 14 showing positive year-on-year growth in net profit, representing 64% [5][7] - Major companies like Muyuan Foods and Wen's Foodstuffs have turned profitable, with net profit growth exceeding 200% [5] Group 4: Financial Metrics - The consumer ETF (159928) has seen a net inflow of nearly 2.6 billion yuan over the past 60 days, with the latest share count reaching nearly 19 billion, maintaining historical highs [8] - The constituent index of the consumer ETF achieved a record net profit of 191.9 billion yuan in the first three quarters of the previous year, marking a year-on-year growth of 29.44% [8] - The latest price-to-earnings ratio for the consumer ETF is 20.37, which is at a low valuation compared to the past decade, indicating a favorable investment opportunity [8][10]

整理 ｜ 彭倩 #Big News# 增长压力之下，雀巢中国换帅 雀巢中国的首位本土 CEO 卸任。 近日，雀巢宣布现任雀巢大中华区董事长兼 CEO 张西强辞任，由现任菲律宾市场负责人马凯思 （Kais Marzouki）接替。这是雀巢集团自去年10月宣布不再将中国市场设立为独立大区后（今年1 月1日起生效），推出的一项人事调整举措。 由于中国市场曾表现颇佳，雀巢曾在2022年为其单独设立大中华区，张西强同年成为雀巢中国首位 本土CEO。中国是雀巢的第二大市场，一直被寄予厚望，张西强在上任时也曾为雀巢中国制定较为乐 观的增长计划：雀巢中国区要在2025年实现600亿小目标，在2030年实现1000亿大目标。 翻看过去3年的财报，雀巢中国区的体量分别为401.6亿元、436亿元和408.69亿元，遇到增长瓶 颈，与张西强曾制定的2025年达到600亿的目标也相差较大。 如今，全球消费市场正处于周期性波动，雀巢在内的一系列外资企业都需要更好的让产品适应当地市 场消费者需求和习惯的变化。 雀巢曾公开表示对中国市场的反思，前 CEO 施耐德曾表示，过去10年，雀巢在中国多项投资没有成 功，如对花生牛奶品牌银鹭的收购， ...

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Views - The company reported strong performance in Q1 2025 with a revenue of 2.36 billion yuan, a year-on-year increase of 8.13%, and a net profit of 390 million yuan, up 28.87% year-on-year [1][2] - The gross margin for 2024 was 71.39%, an increase of 1.46 percentage points year-on-year, driven by a decrease in freight rates [2] - The main brand continues to innovate with new product launches, contributing to a revenue of 8.58 billion yuan in 2024, a year-on-year increase of 19.55% [3][4] Financial Performance - For 2024, the company achieved a total revenue of 10.78 billion yuan, representing a 21.04% year-on-year growth, and a net profit of 1.55 billion yuan, up 30.00% year-on-year [1][4] - The company expects revenues for 2025-2027 to be 12.47 billion yuan, 14.16 billion yuan, and 15.95 billion yuan respectively, with corresponding net profits of 1.81 billion yuan, 2.09 billion yuan, and 2.40 billion yuan [4][5] - The EBITDA for 2024 is projected at 2.27 billion yuan, with a growth rate of 21.04% [4] Product Development - The main brand is in a stable transformation phase, continuously enhancing its product matrix with new launches such as the "Super Membrane Powder Tube" and "Optical Water Emulsion" [4] - The small brand "OR" showed remarkable growth with a revenue increase of 71.14% year-on-year, reaching 368 million yuan [3][4] Market Position - The company is solidifying its position as a leading domestic beauty brand, with a focus on expanding its product offerings and market share [4][5] - The sales expense ratio for 2024 was 47.88%, reflecting an increase of 3.27 percentage points year-on-year, while the management expense ratio decreased by 1.72 percentage points [2]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5] Core Views - The company has shown strong performance in its financial results, with a 2024 revenue of 10.778 billion yuan, representing a year-on-year increase of 21.04%, and a net profit of 1.552 billion yuan, up 30.00% year-on-year [1] - The gross margin has improved, reaching 71.39% in 2024, an increase of 1.46 percentage points year-on-year, and the net profit margin increased to 14.40%, up 0.99 percentage points year-on-year [2] - The main brand continues to innovate with new product launches, contributing to a revenue of 8.581 billion yuan in 2024, a 19.55% increase year-on-year [3] Financial Performance Summary - 2024 revenue: 10.778 billion yuan, up 21.04% year-on-year [1] - 2024 net profit: 1.552 billion yuan, up 30.00% year-on-year [1] - 2025 Q1 revenue: 2.359 billion yuan, up 8.13% year-on-year [1] - 2024 gross margin: 71.39%, up 1.46 percentage points year-on-year [2] - 2024 net profit margin: 14.40%, up 0.99 percentage points year-on-year [2] Product Development and Market Position - The main brand has launched several new products, including the upgraded Ruby and Energy series, enhancing its anti-aging product matrix [3] - The small brand OR has shown remarkable growth with a revenue increase of 71.14% year-on-year, reaching 368 million yuan [3] - The company is expected to maintain its growth trend and increase market share through a solid product strategy [4] Financial Forecast - Expected revenue for 2025-2027: 12.466 billion yuan, 14.159 billion yuan, and 15.953 billion yuan respectively [4] - Expected net profit for 2025-2027: 1.807 billion yuan, 2.095 billion yuan, and 2.402 billion yuan respectively [4] - Corresponding P/E ratios for 2025-2027 are projected at 19x, 16x, and 14x respectively [4]